PEDIATRIX MEDICAL GROUP INC (MD) Fundamental Analysis & Valuation
NYSE:MD • US58502B1061
Current stock price
20.5 USD
-0.48 (-2.29%)
At close:
20.5 USD
0 (0%)
After Hours:
This MD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. MD Profitability Analysis
1.1 Basic Checks
- MD had positive earnings in the past year.
- MD had a positive operating cash flow in the past year.
- The reported net income has been mixed in the past 5 years: MD reported negative net income in multiple years.
- MD had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- MD's Return On Assets of 7.36% is amongst the best of the industry. MD outperforms 87.00% of its industry peers.
- MD's Return On Equity of 19.10% is amongst the best of the industry. MD outperforms 86.00% of its industry peers.
- MD's Return On Invested Capital of 9.88% is fine compared to the rest of the industry. MD outperforms 80.00% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for MD is in line with the industry average of 8.85%.
- The 3 year average ROIC (8.21%) for MD is below the current ROIC(9.88%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.36% | ||
| ROE | 19.1% | ||
| ROIC | 9.88% |
ROA(3y)0.01%
ROA(5y)1.53%
ROE(3y)-0.32%
ROE(5y)4.22%
ROIC(3y)8.21%
ROIC(5y)7.97%
1.3 Margins
- MD's Profit Margin of 8.64% is amongst the best of the industry. MD outperforms 91.00% of its industry peers.
- MD's Profit Margin has improved in the last couple of years.
- MD has a better Operating Margin (12.07%) than 84.00% of its industry peers.
- In the last couple of years the Operating Margin of MD has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.07% | ||
| PM (TTM) | 8.64% | ||
| GM | N/A |
OM growth 3Y5.99%
OM growth 5Y4.02%
PM growth 3Y36.96%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. MD Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MD is still creating some value.
- Compared to 1 year ago, MD has less shares outstanding
- Compared to 5 years ago, MD has less shares outstanding
- Compared to 1 year ago, MD has an improved debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 2.06 indicates that MD is not a great score, but indicates only limited risk for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 2.06, MD is in line with its industry, outperforming 52.00% of the companies in the same industry.
- MD has a debt to FCF ratio of 2.36. This is a good value and a sign of high solvency as MD would need 2.36 years to pay back of all of its debts.
- Looking at the Debt to FCF ratio, with a value of 2.36, MD is in the better half of the industry, outperforming 74.00% of the companies in the same industry.
- MD has a Debt/Equity ratio of 0.66. This is a neutral value indicating MD is somewhat dependend on debt financing.
- The Debt to Equity ratio of MD (0.66) is comparable to the rest of the industry.
- Although MD's pure debt/equity ratio does not look good, it has limited outstanding debt compared to the Free Cash Flow. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 2.36 | ||
| Altman-Z | 2.06 |
ROIC/WACC1.18
WACC8.34%
2.3 Liquidity
- MD has a Current Ratio of 1.66. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
- The Current ratio of MD (1.66) is better than 68.00% of its industry peers.
- A Quick Ratio of 1.66 indicates that MD should not have too much problems paying its short term obligations.
- The Quick ratio of MD (1.66) is better than 70.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.66 | ||
| Quick Ratio | 1.66 |
3. MD Growth Analysis
3.1 Past
- MD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.24%, which is quite impressive.
- Measured over the past years, MD shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.01% on average per year.
- MD shows a decrease in Revenue. In the last year, the revenue decreased by -4.92%.
- The Revenue has been growing slightly by 1.99% on average over the past years.
EPS 1Y (TTM)36.24%
EPS 3Y6.72%
EPS 5Y10.01%
EPS Q2Q%-1.96%
Revenue 1Y (TTM)-4.92%
Revenue growth 3Y-0.99%
Revenue growth 5Y1.99%
Sales Q2Q%-1.71%
3.2 Future
- MD is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.99% yearly.
- The Revenue is expected to grow by 3.93% on average over the next years.
EPS Next Y13.36%
EPS Next 2Y8.67%
EPS Next 3Y4.87%
EPS Next 5Y0.99%
Revenue Next Year1.07%
Revenue Next 2Y1.84%
Revenue Next 3Y2.77%
Revenue Next 5Y3.93%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. MD Valuation Analysis
4.1 Price/Earnings Ratio
- MD is valuated reasonably with a Price/Earnings ratio of 10.10.
- Compared to the rest of the industry, the Price/Earnings ratio of MD indicates a rather cheap valuation: MD is cheaper than 91.00% of the companies listed in the same industry.
- When comparing the Price/Earnings ratio of MD to the average of the S&P500 Index (24.88), we can say MD is valued rather cheaply.
- A Price/Forward Earnings ratio of 8.91 indicates a reasonable valuation of MD.
- Based on the Price/Forward Earnings ratio, MD is valued cheaply inside the industry as 93.00% of the companies are valued more expensively.
- The average S&P500 Price/Forward Earnings ratio is at 22.19. MD is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.1 | ||
| Fwd PE | 8.91 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MD indicates a rather cheap valuation: MD is cheaper than 88.00% of the companies listed in the same industry.
- MD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MD is cheaper than 90.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.74 | ||
| EV/EBITDA | 6.78 |
4.3 Compensation for Growth
- MD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- MD has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.76
PEG (5Y)1.01
EPS Next 2Y8.67%
EPS Next 3Y4.87%
5. MD Dividend Analysis
5.1 Amount
- MD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
MD Fundamentals: All Metrics, Ratios and Statistics
20.5
-0.48 (-2.29%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-19 2026-02-19/bmo
Earnings (Next)05-04 2026-05-04/bmo
Inst Owners102.64%
Inst Owner Change1.24%
Ins Owners1.94%
Ins Owner Change-0.8%
Market Cap1.70B
Revenue(TTM)1.91B
Net Income(TTM)165.39M
Analysts78.67
Price Target21.93 (6.98%)
Short Float %3.35%
Short Ratio3.54
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.87%
Min EPS beat(2)-9.94%
Max EPS beat(2)39.68%
EPS beat(4)3
Avg EPS beat(4)20.9%
Min EPS beat(4)-9.94%
Max EPS beat(4)39.68%
EPS beat(8)7
Avg EPS beat(8)17.99%
EPS beat(12)7
Avg EPS beat(12)8.59%
EPS beat(16)8
Avg EPS beat(16)5.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.49%
Min Revenue beat(2)-1.41%
Max Revenue beat(2)0.42%
Revenue beat(4)1
Avg Revenue beat(4)-1.1%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.42%
Revenue beat(8)2
Avg Revenue beat(8)-1.43%
Revenue beat(12)2
Avg Revenue beat(12)-2.28%
Revenue beat(16)2
Avg Revenue beat(16)-2.52%
PT rev (1m)-5.15%
PT rev (3m)-5.15%
EPS NQ rev (1m)-1.3%
EPS NQ rev (3m)-1.3%
EPS NY rev (1m)2.14%
EPS NY rev (3m)2.14%
Revenue NQ rev (1m)-1.72%
Revenue NQ rev (3m)-1.72%
Revenue NY rev (1m)-1.59%
Revenue NY rev (3m)-1.59%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.1 | ||
| Fwd PE | 8.91 | ||
| P/S | 0.89 | ||
| P/FCF | 6.74 | ||
| P/OCF | 6.28 | ||
| P/B | 1.97 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.78 |
EPS(TTM)2.03
EY9.9%
EPS(NY)2.3
Fwd EY11.23%
FCF(TTM)3.04
FCFY14.85%
OCF(TTM)3.27
OCFY15.93%
SpS23.06
BVpS10.43
TBVpS-4.96
PEG (NY)0.76
PEG (5Y)1.01
Graham Number21.83
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.36% | ||
| ROE | 19.1% | ||
| ROCE | 12.93% | ||
| ROIC | 9.88% | ||
| ROICexc | 13.71% | ||
| ROICexgc | 1686.9% | ||
| OM | 12.07% | ||
| PM (TTM) | 8.64% | ||
| GM | N/A | ||
| FCFM | 13.2% |
ROA(3y)0.01%
ROA(5y)1.53%
ROE(3y)-0.32%
ROE(5y)4.22%
ROIC(3y)8.21%
ROIC(5y)7.97%
ROICexc(3y)10.42%
ROICexc(5y)9.77%
ROICexgc(3y)618.91%
ROICexgc(5y)394.62%
ROCE(3y)10.75%
ROCE(5y)10.43%
ROICexgc growth 3Y208.98%
ROICexgc growth 5Y85.34%
ROICexc growth 3Y17.7%
ROICexc growth 5Y11.82%
OM growth 3Y5.99%
OM growth 5Y4.02%
PM growth 3Y36.96%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.85
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 2.36 | ||
| Debt/EBITDA | 2.26 | ||
| Cap/Depr | 84.57% | ||
| Cap/Sales | 0.96% | ||
| Interest Coverage | 6.72 | ||
| Cash Conversion | 107.19% | ||
| Profit Quality | 152.75% | ||
| Current Ratio | 1.66 | ||
| Quick Ratio | 1.66 | ||
| Altman-Z | 2.06 |
F-Score8
WACC8.34%
ROIC/WACC1.18
Cap/Depr(3y)81.68%
Cap/Depr(5y)85.74%
Cap/Sales(3y)1.24%
Cap/Sales(5y)1.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.24%
EPS 3Y6.72%
EPS 5Y10.01%
EPS Q2Q%-1.96%
EPS Next Y13.36%
EPS Next 2Y8.67%
EPS Next 3Y4.87%
EPS Next 5Y0.99%
Revenue 1Y (TTM)-4.92%
Revenue growth 3Y-0.99%
Revenue growth 5Y1.99%
Sales Q2Q%-1.71%
Revenue Next Year1.07%
Revenue Next 2Y1.84%
Revenue Next 3Y2.77%
Revenue Next 5Y3.93%
EBIT growth 1Y25.81%
EBIT growth 3Y4.93%
EBIT growth 5Y6.1%
EBIT Next Year16.33%
EBIT Next 3Y6.84%
EBIT Next 5YN/A
FCF growth 1Y36.89%
FCF growth 3Y22.56%
FCF growth 5Y7.52%
OCF growth 1Y31.23%
OCF growth 3Y17.54%
OCF growth 5Y5.79%
PEDIATRIX MEDICAL GROUP INC / MD Fundamental Analysis FAQ
What is the ChartMill fundamental rating of PEDIATRIX MEDICAL GROUP INC (MD) stock?
ChartMill assigns a fundamental rating of 6 / 10 to MD.
What is the valuation status for MD stock?
ChartMill assigns a valuation rating of 8 / 10 to PEDIATRIX MEDICAL GROUP INC (MD). This can be considered as Undervalued.
How profitable is PEDIATRIX MEDICAL GROUP INC (MD) stock?
PEDIATRIX MEDICAL GROUP INC (MD) has a profitability rating of 7 / 10.
What are the PE and PB ratios of PEDIATRIX MEDICAL GROUP INC (MD) stock?
The Price/Earnings (PE) ratio for PEDIATRIX MEDICAL GROUP INC (MD) is 10.1 and the Price/Book (PB) ratio is 1.97.